0001209191-18-035400.txt : 20180604 0001209191-18-035400.hdr.sgml : 20180604 20180604205115 ACCESSION NUMBER: 0001209191-18-035400 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180523 FILED AS OF DATE: 20180604 DATE AS OF CHANGE: 20180604 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HESTERBERG LYNDAL K. CENTRAL INDEX KEY: 0001689836 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37648 FILM NUMBER: 18879885 MAIL ADDRESS: STREET 1: 1010 ATLANTIC AVENUE STREET 2: SUITE 102 CITY: ALAMEDA STATE: CA ZIP: 94501 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OncoCyte Corp CENTRAL INDEX KEY: 0001642380 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 271041563 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1010 ATLANTIC AVENUE STREET 2: SUITE 102 CITY: ALAMEDA STATE: CA ZIP: 94501 BUSINESS PHONE: 510-775-0515 MAIL ADDRESS: STREET 1: 1010 ATLANTIC AVENUE STREET 2: SUITE 102 CITY: ALAMEDA STATE: CA ZIP: 94501 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-05-23 0 0001642380 OncoCyte Corp OCX 0001689836 HESTERBERG LYNDAL K. 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501 0 1 0 0 Sr VP, Research & Development Option to Purchase Common Stock 2.35 2018-05-23 4 A 0 150000 0.00 A 2028-05-22 Common Stock 150000 150000 D Option to Purchase Common Stock 4.70 2027-02-16 Common Stock 14400 14400 D Option to Purchase Common Stock 4.05 2026-10-31 Common Stock 125000 125000 D Option to Purchase Common Stock 3.06 2026-02-15 Common Stock 25000 25000 D These options vest as to one-third of the shares on each of the completion of the clinical utility study for OncoCyte's DetermaVu product candidate, the filing of the Medicare dossier for the Medicare local coverage determination, and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate. One quarter of the options vested on October 31, 2017, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant. One quarter of the options vested on February 15, 2017 and one quarter vested on February 15, 2018, and the balance shall vest upon the attainment of certain product development milestones, in each case depending upon continuous employment by the Company. /s/Lyndal K. Hesterberg 2018-06-01